University of Pennsylvania Cancer Center
Last Modified: May 19, 1998
In a second analysis of the study presented yesterday, researchers found that the risk of developing breast cancer was reduced by 58% in women taking Raloxifene, compared to women receiving a placebo. This dramatic reduction was observed in postmenopausal women being treated for osteoporosis who had no history of breast cancer. The researchers conclude that there is substantial evidence for a profound reduction in the risk of developing breast cancer for patients taking Raloxifene.
Raloxifene has target-site specific estrogen agonist effects on bone and lipid an antagonist effects on breast and uterine tissue, via modulation an high affinity binding to the estrogen receptor on tumor cells.
Sep 1, 2014 - Three medications -- the selective estrogen receptor modulators tamoxifen and raloxifene, and tibolone, a drug not approved in the United States but used in many other countries to treat menopausal symptoms -- may reduce the risk for primary breast cancer. However, the three drugs are variously associated with an increased risk of thromboembolic events, endometrial cancer or stroke, according to a study published online Sept. 15 in the Annals of Internal Medicine.